MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe…
Novartis Cosentyx receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Cosentyx is the only IL-17A inhibitor approved for this population, and the…
